GlaxoSmithKline agreed to acquire Canadian biotech 35Pharma for $950 million to add the company’s pulmonary hypertension drug program to GSK’s cardiovascular and rare‑disease pipeline. The purchase grants GSK control of clinical assets aimed at pulmonary vascular disease and positions the company to expand in specialized cardiopulmonary indications. GSK’s investment reflects continued big‑pharma appetite for in‑licensing or acquiring niche programs with clear development paths. The deal also hints at strategic interest in adjacent metabolic indications as companies repurpose cardiometabolic assets across high‑value therapeutic areas.